Regulative effects of curcumin spice administration on gut microbiota and its pharmacological implications

References

• Heger M, van Golen RF, Broekgaarden M, et al. The molecular basis for the pharmacokinetics and pharmacodynamics of curcumin and its metabolites in relation to cancer. Pharmacol Rev. 2013;66:222–4.
   PubMed Web of Science ®Google Scholar
• Sreedhar R, Arumugam S, Thandavarayan RA, et al. Curcumin as a therapeutic agent in the chemoprevention of inflammatory bowel disease. Drug Discov Today. 2016;21:843–849.
   PubMed Web of Science ®Google Scholar
• Gupta SC, Patchva S, Aggarwal BB. Therapeutic roles of curcumin: lessons learned from clinical trials. Aaps J. 2013;15:195–218.
   PubMed Web of Science ®Google Scholar
• Gupta SC, Sung B, Kim J, et al. Multitargeting by turmeric, the golden spice: from kitchen to clinic. Mol Nutr Food Res. 2013;57:1510–1528.
   PubMed Web of Science ®Google Scholar
• Gupta SC, Prasad S, Kim JH, et al. Multitargeting by curcumin as revealed by molecular interaction studies. Nat Prod Rep. 2011;28:1937–1955.
   PubMed Web of Science ®Google Scholar
• Anand P, Kunnumakkara AB, Newman RA, et al. Bioavailability of curcumin: problems and promises. Mol Pharm. 2007;4:807–818.
   PubMed Web of Science ®Google Scholar
• Ji HF, Shen L. Can improving bioavailability improve the bioactivity of curcumin? Trends Pharmacol Sci. 2014;35:265–266.
   PubMed Web of Science ®Google Scholar
• Lao CD, Ruffin MT, Normolle D. Dose escalation of a curcuminoid formulation. BMC Complement Altern Med. 2006;6:10.
   PubMedGoogle Scholar
• Nicholson JK, Holmes E, Kinross J, et al. Host-gut microbiota metabolic interactions. Science. 2012;336:1262–1267.
   PubMed Web of Science ®Google Scholar
• Qin N, Yang F, Li A, et al. Alterations of the human gut microbiome in liver cirrhosis. Nature. 2014;513:59–64.
   PubMed Web of Science ®Google Scholar
• Karlsson FH, Tremaroli V, Nookaew I, et al. Gut metagenome in European women with normal, impaired and diabetic glucose control. Nature. 2013;498:99–103.
   PubMed Web of Science ®Google Scholar
• Abu-Shanab A, Quigley EM. The role of the gut microbiota in nonalcoholic fatty liver disease. Nat Rev Gastroenterol Hepatol. 2010;7:691–701.
   PubMed Web of Science ®Google Scholar
• Shen L, Ji HF. Intestinal microbiota and metabolic diseases: pharmacological Implications. Trends Pharmacol Sci. 2016;37:169–171.
   PubMed Web of Science ®Google Scholar
• Feng W, Wang H, Zhang P, et al. Modulation of gut microbiota contributes to curcumin-mediated attenuation of hepatic steatosis in rats. Biochim Biophys Acta. 2017;1861:1801–1812.
   PubMed Web of Science ®Google Scholar
• Le Chatelier E, Nielsen T, Qin J, et al. Richness of human gut microbiome correlates with metabolic markers. Nature. 2013;500:541–546.
   PubMed Web of Science ®Google Scholar
• Cotillard A, Kennedy SP, Kong LC, et al. Dietary intervention impact on gut microbial gene richness. Nature. 2013;500:585–588.
   PubMed Web of Science ®Google Scholar
• Arora T, Bäckhed F. The gut microbiota and metabolic disease: current understanding and future perspectives. J Intern Med. 2016;280:339–349.
   PubMed Web of Science ®Google Scholar
• Ridaura VK, Faith JJ, Rey FE, et al. Gut microbiota from twins discordant for obesity modulate metabolism in mice. Science. 2013;341:1241214.
   PubMed Web of Science ®Google Scholar
• Turnbaugh PJ, Hamady M, Yatsunenko T. A core gut microbiome in obese and lean twins. Nature. 2009;457:480–484.
   PubMed Web of Science ®Google Scholar
• Ott SJ, Musfeldt M, Wenderoth DF, et al. Reduction in diversity of the colonic mucosa associated bacterial microflora in patients with active inflammatory bowel disease. Gut. 2004;53:685–693.
   PubMed Web of Science ®Google Scholar
• Larsen N, Vogensen FK, van den Berg FWJ, et al. Gut microbiota in human adults with type 2 diabetes differs from non-diabetic adults. PLoS One. 2010;5:e9085.
   PubMed Web of Science ®Google Scholar
• Shen L, Ji HF. The pharmacology of curcumin: is it the degradation products? Trends Mol Med. 2012;18:138–144.
   PubMed Web of Science ®Google Scholar
• Shen L, Ji HF. Contribution of degradation products to the anticancer activity of curcumin. Clin Cancer Res. 2009;15:7108.
   Web of Science ®Google Scholar
• Shen L, Liu CC, An CY, et al. How does curcumin work with poor bioavailability? Clues from experimental and theoretical studies. Sci Rep. 2016;6 18:20872.
   PubMed Web of Science ®Google Scholar
• Shen L, Ji HF. Insights into the inhibition of xanthine oxidase by curcumin. Bioorg Med Chem Lett. 2009;19:5990–5993.
   PubMed Web of Science ®Google Scholar
• Herath W, Ferreira D, Khan IA. Microbial metabolism. Part 7: curcumin. Nat Prod Res. 2007;21:444–450.
   PubMed Web of Science ®Google Scholar
• Hassaninasab A, Hashimoto Y, Tomita-Yokotani K, et al. Discovery of the curcumin metabolic pathway involving a unique enzyme in an intestinal microorganism. Proc Natl Acad Sci USA. 2011;108:6615–6620.
   PubMed Web of Science ®Google Scholar